Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis
Autor*in: |
Dominika Wcisło-Dziadecka [verfasserIn] Beniamin Grabarek [verfasserIn] Andrzej Swinarew [verfasserIn] Beata Rozwadowska [verfasserIn] Nikola Zmarzły [verfasserIn] Joanna Gola [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2020 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Advances in Dermatology and Allergology - Termedia Publishing House, 2016, 37(2020), 2, Seite 262-268 |
---|---|
Übergeordnetes Werk: |
volume:37 ; year:2020 ; number:2 ; pages:262-268 |
Links: |
Link aufrufen |
---|
DOI / URN: |
10.5114/ada.2020.94847 |
---|
Katalog-ID: |
DOAJ067001424 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ067001424 | ||
003 | DE-627 | ||
005 | 20230501185141.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230228s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.5114/ada.2020.94847 |2 doi | |
035 | |a (DE-627)DOAJ067001424 | ||
035 | |a (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RL1-803 | |
050 | 0 | |a RC31-1245 | |
100 | 0 | |a Dominika Wcisło-Dziadecka |e verfasserin |4 aut | |
245 | 1 | 0 | |a Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
650 | 4 | |a anti-tnf therapy | |
650 | 4 | |a psoriasis | |
650 | 4 | |a molecular marker | |
650 | 4 | |a resistance in therapy | |
650 | 4 | |a personalized medicine | |
653 | 0 | |a Dermatology | |
653 | 0 | |a Internal medicine | |
700 | 0 | |a Beniamin Grabarek |e verfasserin |4 aut | |
700 | 0 | |a Andrzej Swinarew |e verfasserin |4 aut | |
700 | 0 | |a Beata Rozwadowska |e verfasserin |4 aut | |
700 | 0 | |a Nikola Zmarzły |e verfasserin |4 aut | |
700 | 0 | |a Joanna Gola |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Advances in Dermatology and Allergology |d Termedia Publishing House, 2016 |g 37(2020), 2, Seite 262-268 |w (DE-627)647656531 |w (DE-600)2596142-1 |x 22990046 |7 nnns |
773 | 1 | 8 | |g volume:37 |g year:2020 |g number:2 |g pages:262-268 |
856 | 4 | 0 | |u https://doi.org/10.5114/ada.2020.94847 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 |z kostenfrei |
856 | 4 | 0 | |u https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1642-395X |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/2299-0046 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 37 |j 2020 |e 2 |h 262-268 |
author_variant |
d w d dwd b g bg a s as b r br n z nz j g jg |
---|---|
matchkey_str |
article:22990046:2020----::opeesvmlclrnciiaaayioaaiuaadtnrethrpuiptnil |
hierarchy_sort_str |
2020 |
callnumber-subject-code |
RL |
publishDate |
2020 |
allfields |
10.5114/ada.2020.94847 doi (DE-627)DOAJ067001424 (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920 DE-627 ger DE-627 rakwb eng RL1-803 RC31-1245 Dominika Wcisło-Dziadecka verfasserin aut Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine Dermatology Internal medicine Beniamin Grabarek verfasserin aut Andrzej Swinarew verfasserin aut Beata Rozwadowska verfasserin aut Nikola Zmarzły verfasserin aut Joanna Gola verfasserin aut In Advances in Dermatology and Allergology Termedia Publishing House, 2016 37(2020), 2, Seite 262-268 (DE-627)647656531 (DE-600)2596142-1 22990046 nnns volume:37 year:2020 number:2 pages:262-268 https://doi.org/10.5114/ada.2020.94847 kostenfrei https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 kostenfrei https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html kostenfrei https://doaj.org/toc/1642-395X Journal toc kostenfrei https://doaj.org/toc/2299-0046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2020 2 262-268 |
spelling |
10.5114/ada.2020.94847 doi (DE-627)DOAJ067001424 (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920 DE-627 ger DE-627 rakwb eng RL1-803 RC31-1245 Dominika Wcisło-Dziadecka verfasserin aut Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine Dermatology Internal medicine Beniamin Grabarek verfasserin aut Andrzej Swinarew verfasserin aut Beata Rozwadowska verfasserin aut Nikola Zmarzły verfasserin aut Joanna Gola verfasserin aut In Advances in Dermatology and Allergology Termedia Publishing House, 2016 37(2020), 2, Seite 262-268 (DE-627)647656531 (DE-600)2596142-1 22990046 nnns volume:37 year:2020 number:2 pages:262-268 https://doi.org/10.5114/ada.2020.94847 kostenfrei https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 kostenfrei https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html kostenfrei https://doaj.org/toc/1642-395X Journal toc kostenfrei https://doaj.org/toc/2299-0046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2020 2 262-268 |
allfields_unstemmed |
10.5114/ada.2020.94847 doi (DE-627)DOAJ067001424 (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920 DE-627 ger DE-627 rakwb eng RL1-803 RC31-1245 Dominika Wcisło-Dziadecka verfasserin aut Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine Dermatology Internal medicine Beniamin Grabarek verfasserin aut Andrzej Swinarew verfasserin aut Beata Rozwadowska verfasserin aut Nikola Zmarzły verfasserin aut Joanna Gola verfasserin aut In Advances in Dermatology and Allergology Termedia Publishing House, 2016 37(2020), 2, Seite 262-268 (DE-627)647656531 (DE-600)2596142-1 22990046 nnns volume:37 year:2020 number:2 pages:262-268 https://doi.org/10.5114/ada.2020.94847 kostenfrei https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 kostenfrei https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html kostenfrei https://doaj.org/toc/1642-395X Journal toc kostenfrei https://doaj.org/toc/2299-0046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2020 2 262-268 |
allfieldsGer |
10.5114/ada.2020.94847 doi (DE-627)DOAJ067001424 (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920 DE-627 ger DE-627 rakwb eng RL1-803 RC31-1245 Dominika Wcisło-Dziadecka verfasserin aut Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine Dermatology Internal medicine Beniamin Grabarek verfasserin aut Andrzej Swinarew verfasserin aut Beata Rozwadowska verfasserin aut Nikola Zmarzły verfasserin aut Joanna Gola verfasserin aut In Advances in Dermatology and Allergology Termedia Publishing House, 2016 37(2020), 2, Seite 262-268 (DE-627)647656531 (DE-600)2596142-1 22990046 nnns volume:37 year:2020 number:2 pages:262-268 https://doi.org/10.5114/ada.2020.94847 kostenfrei https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 kostenfrei https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html kostenfrei https://doaj.org/toc/1642-395X Journal toc kostenfrei https://doaj.org/toc/2299-0046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2020 2 262-268 |
allfieldsSound |
10.5114/ada.2020.94847 doi (DE-627)DOAJ067001424 (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920 DE-627 ger DE-627 rakwb eng RL1-803 RC31-1245 Dominika Wcisło-Dziadecka verfasserin aut Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine Dermatology Internal medicine Beniamin Grabarek verfasserin aut Andrzej Swinarew verfasserin aut Beata Rozwadowska verfasserin aut Nikola Zmarzły verfasserin aut Joanna Gola verfasserin aut In Advances in Dermatology and Allergology Termedia Publishing House, 2016 37(2020), 2, Seite 262-268 (DE-627)647656531 (DE-600)2596142-1 22990046 nnns volume:37 year:2020 number:2 pages:262-268 https://doi.org/10.5114/ada.2020.94847 kostenfrei https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 kostenfrei https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html kostenfrei https://doaj.org/toc/1642-395X Journal toc kostenfrei https://doaj.org/toc/2299-0046 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 37 2020 2 262-268 |
language |
English |
source |
In Advances in Dermatology and Allergology 37(2020), 2, Seite 262-268 volume:37 year:2020 number:2 pages:262-268 |
sourceStr |
In Advances in Dermatology and Allergology 37(2020), 2, Seite 262-268 volume:37 year:2020 number:2 pages:262-268 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine Dermatology Internal medicine |
isfreeaccess_bool |
true |
container_title |
Advances in Dermatology and Allergology |
authorswithroles_txt_mv |
Dominika Wcisło-Dziadecka @@aut@@ Beniamin Grabarek @@aut@@ Andrzej Swinarew @@aut@@ Beata Rozwadowska @@aut@@ Nikola Zmarzły @@aut@@ Joanna Gola @@aut@@ |
publishDateDaySort_date |
2020-01-01T00:00:00Z |
hierarchy_top_id |
647656531 |
id |
DOAJ067001424 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ067001424</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501185141.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.5114/ada.2020.94847</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ067001424</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RL1-803</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Dominika Wcisło-Dziadecka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-tnf therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">psoriasis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">molecular marker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">resistance in therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dermatology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beniamin Grabarek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrzej Swinarew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beata Rozwadowska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nikola Zmarzły</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joanna Gola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Advances in Dermatology and Allergology</subfield><subfield code="d">Termedia Publishing House, 2016</subfield><subfield code="g">37(2020), 2, Seite 262-268</subfield><subfield code="w">(DE-627)647656531</subfield><subfield code="w">(DE-600)2596142-1</subfield><subfield code="x">22990046</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:37</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:262-268</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.5114/ada.2020.94847</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1642-395X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2299-0046</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">37</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="h">262-268</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Dominika Wcisło-Dziadecka |
spellingShingle |
Dominika Wcisło-Dziadecka misc RL1-803 misc RC31-1245 misc anti-tnf therapy misc psoriasis misc molecular marker misc resistance in therapy misc personalized medicine misc Dermatology misc Internal medicine Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis |
authorStr |
Dominika Wcisło-Dziadecka |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)647656531 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RL1-803 |
illustrated |
Not Illustrated |
issn |
22990046 |
topic_title |
RL1-803 RC31-1245 Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis anti-tnf therapy psoriasis molecular marker resistance in therapy personalized medicine |
topic |
misc RL1-803 misc RC31-1245 misc anti-tnf therapy misc psoriasis misc molecular marker misc resistance in therapy misc personalized medicine misc Dermatology misc Internal medicine |
topic_unstemmed |
misc RL1-803 misc RC31-1245 misc anti-tnf therapy misc psoriasis misc molecular marker misc resistance in therapy misc personalized medicine misc Dermatology misc Internal medicine |
topic_browse |
misc RL1-803 misc RC31-1245 misc anti-tnf therapy misc psoriasis misc molecular marker misc resistance in therapy misc personalized medicine misc Dermatology misc Internal medicine |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Advances in Dermatology and Allergology |
hierarchy_parent_id |
647656531 |
hierarchy_top_title |
Advances in Dermatology and Allergology |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)647656531 (DE-600)2596142-1 |
title |
Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis |
ctrlnum |
(DE-627)DOAJ067001424 (DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920 |
title_full |
Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis |
author_sort |
Dominika Wcisło-Dziadecka |
journal |
Advances in Dermatology and Allergology |
journalStr |
Advances in Dermatology and Allergology |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2020 |
contenttype_str_mv |
txt |
container_start_page |
262 |
author_browse |
Dominika Wcisło-Dziadecka Beniamin Grabarek Andrzej Swinarew Beata Rozwadowska Nikola Zmarzły Joanna Gola |
container_volume |
37 |
class |
RL1-803 RC31-1245 |
format_se |
Elektronische Aufsätze |
author-letter |
Dominika Wcisło-Dziadecka |
doi_str_mv |
10.5114/ada.2020.94847 |
author2-role |
verfasserin |
title_sort |
comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis |
callnumber |
RL1-803 |
title_auth |
Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
2 |
title_short |
Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis |
url |
https://doi.org/10.5114/ada.2020.94847 https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920 https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html https://doaj.org/toc/1642-395X https://doaj.org/toc/2299-0046 |
remote_bool |
true |
author2 |
Beniamin Grabarek Andrzej Swinarew Beata Rozwadowska Nikola Zmarzły Joanna Gola |
author2Str |
Beniamin Grabarek Andrzej Swinarew Beata Rozwadowska Nikola Zmarzły Joanna Gola |
ppnlink |
647656531 |
callnumber-subject |
RL - Dermatology |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.5114/ada.2020.94847 |
callnumber-a |
RL1-803 |
up_date |
2024-07-03T23:04:53.910Z |
_version_ |
1803600940405620736 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ067001424</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230501185141.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.5114/ada.2020.94847</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ067001424</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJfe128dfcb16145fe8e5f7a723c928920</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RL1-803</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC31-1245</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Dominika Wcisło-Dziadecka</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Comprehensive molecular and clinical analysis of adalimumab and etanercept therapeutic potential in patients with psoriatic arthritis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-tnf therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">psoriasis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">molecular marker</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">resistance in therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">personalized medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Dermatology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Internal medicine</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beniamin Grabarek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrzej Swinarew</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Beata Rozwadowska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nikola Zmarzły</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joanna Gola</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Advances in Dermatology and Allergology</subfield><subfield code="d">Termedia Publishing House, 2016</subfield><subfield code="g">37(2020), 2, Seite 262-268</subfield><subfield code="w">(DE-627)647656531</subfield><subfield code="w">(DE-600)2596142-1</subfield><subfield code="x">22990046</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:37</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:262-268</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.5114/ada.2020.94847</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/fe128dfcb16145fe8e5f7a723c928920</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.termedia.pl/Comprehensive-molecular-and-clinical-analysis-of-adalimumab-and-etanercept-therapeutic-potential-in-patients-with-psoriatic-arthritis,7,40521,1,1.html</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1642-395X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2299-0046</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">37</subfield><subfield code="j">2020</subfield><subfield code="e">2</subfield><subfield code="h">262-268</subfield></datafield></record></collection>
|
score |
7.401269 |